International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing.

ABSTRACT:

Objective

To evaluate perceptions toward pharmacogenetic testing of patients undergoing percutaneous coronary intervention (PCI) who are prescribed dual antiplatelet therapy (DAPT) and whether geographical differences in these perceptions exist.

Participants and methods

TAILOR-PCI is the largest genotype-based cardiovascular clinical trial randomizing participants to conventional DAPT or prospective genotyping-guided DAPT. Enrolled patients completed surveys before and 6 months after randomization.

Results

A total of 1327 patients completed baseline surveys of whom 28, 29, and 43% were from Korea, Canada and the USA, respectively. Most patients (77%) valued identifying pharmacogenetic variants; however, fewer Koreans (44%) as compared with Canadians (91%) and USA (89%

SUBMITTER: Pereira NL 

PROVIDER: S-EPMC6476684 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature